Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

ARID5B polymorphism confers an increased risk to acquire specific MLL rearrangements in early childhood leukemia

Authors: Mariana Emerenciano, Thayana Conceição Barbosa, Bruno Almeida Lopes, Caroline Barbieri Blunck, Alessandra Faro, Camilla Andrade, Claus Meyer, Rolf Marschalek, Maria S Pombo-de-Oliveira, The Brazilian Collaborative Study Group of Infant Acute Leukemia

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Acute leukemia in early age (EAL) is characterized by acquired genetic alterations such as MLL rearrangements (MLL-r). The aim of this case-controlled study was to investigate whether single nucleotide polymorphisms (SNPs) of IKZF1, ARID5B, and CEBPE could be related to the onset of EAL cases (<24 months-old at diagnosis).

Methods

The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. Logistic regression was used to evaluate the association between SNPs of cases and controls, adjusted on skin color and/or age. The risk was determined by calculating odds ratios (ORs) with 95% confidence interval (CI).

Results

Children with the IKZF1 SNP had an increased risk of developing MLL-germline ALL in white children. The heterozygous/mutant genotype in ARID5B rs10994982 significantly increased the risk for MLL-germline leukemia in white and non-white children (OR 2.60, 95% CI: 1.09-6.18 and OR 3.55, 95% CI: 1.57-8.68, respectively). The heterozygous genotype in ARID5B rs10821936 increased the risk for MLL-r leukemia in both white and non-white (OR 2.06, 95% CI: 1.12-3.79 and OR 2.36, 95% CI: 1.09-5.10, respectively). Furthermore, ARID5B rs10821936 conferred increased risk for MLL-MLLT3 positive cases (OR 7.10, 95% CI:1.54-32.68). Our data do not show evidence that CEBPE rs2239633 confers increased genetic susceptibility to EAL.

Conclusions

IKZF1 and CEBPE variants seem to play a minor role in genetic susceptibility to EAL, while ARID5B rs10821936 increased the risk of MLL-MLLT3. This result shows that genetic susceptibility could be associated with the differences regarding MLL breakpoints and partner genes.
Appendix
Available only for authorised users
Literature
1.
Pieters R, Schrappe M, de LP, Hann I, De RG, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li C, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007, 370: 240-250. 10.1016/S0140-6736(07)61126-X.CrossRefPubMed
2.
Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJ, Leszl A, Litvinko N, Nigro LL, Morimoto A, Perot C, Pieters R, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, et al: Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009, 114: 2489-2496. 10.1182/blood-2009-04-215152.CrossRefPubMedPubMedCentral
3.
Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel CM, Chan LC, Greaves M: In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature. 1993, 363: 358-360. 10.1038/363358a0.CrossRefPubMed
4.
Greaves MF, Wiemels J: Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003, 3: 639-649. 10.1038/nrc1164.CrossRefPubMed
5.
Alexander FE, Patheal SL, Biondi A, Brandalise S, Cabrera ME, Chan LC, Chen Z, Cimino G, Cordoba JC, Gu LJ, Hussein H, Ishii E, Kamel AM, Labra S, Magalhães IQ, Mizutani S, Petridou E, de Oliveira MP, Yuen P, Wiemels JL, Greaves MF: Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res. 2001, 61: 2542-2546.PubMed
6.
Pombo-de-Oliveira MS, Koifman S: Infant acute leukemia and maternal exposures during pregnancy. Cancer Epidemiol Biomarkers Prev. 2006, 15: 2336-2341. 10.1158/1055-9965.EPI-06-0031.CrossRefPubMed
7.
Ferreira JD, Couto AC, Pombo-de-Oliveira MS, Koifman S, Brazilian Collaborative Study Group of Infant Acute Leukemia: In utero pesticide exposure and leukemia in Brazilian children < 2 years of age. Environ Health Perspect. 2013, 121: 269-275.PubMed
8.
Vijayakrishnan J, Houlston RS: Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica. 2010, 95: 1405-1414. 10.3324/haematol.2010.022095.CrossRefPubMedPubMedCentral
9.
Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexander FE, Greaves MF, United Kingdom Childhood Cancer Study investigators: Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A. 2001, 98: 4004-4009. 10.1073/pnas.061408298.CrossRefPubMedPubMedCentral
10.
Smith MT, Wang Y, Skibola CF, Rollinson S, Wiemels JL, Roman E, Roddam P, Cartwright R, Morgan G: Low NAD (P) H: quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood. 2002, 100: 4590-4593. 10.1182/blood-2001-12-0264.CrossRefPubMed
11.
Zanrosso CW, Emerenciano M, Goncalves BA, Faro A, Koifman S, Pombo-de-Oliveira MS: N-acetyltransferase 2 polymorphisms and susceptibility to infant leukemia with maternal exposure to dipyrone during pregnancy. Cancer Epidemiol Biomarkers Prev. 2010, 19: 3037-3043. 10.1158/1055-9965.EPI-10-0508.CrossRefPubMed
12.
Ross JA, Linabery AM, Blommer CN, Langer EK, Spector LG, Hilden JM, Heerema NA, Radolff GA, Tower RL, Davies SM: Genetic variants modify susceptibility to leukemia in infants: a Children’s Oncology Group report. Pediatr Blood Cancer. 2013, 60: 31-34. 10.1002/pbc.24131.CrossRefPubMed
13.
Gonçalves BAA, Vasconcelos GM, Thuler LC, Andrade C, Faro A, Pombo-de-Oliveira MS, Brazilian Collaborative Study Group of Infant Acute Leukemia: NQO1 rs1800566 (C609T), PON1 rs662 (Q192R), and PON1 rs854560 (L55M) polymorphisms segregate the risk of childhood acute leukemias according to age range distribution. Cancer Causes Control. 2012, 23: 1811-1819. 10.1007/s10552-012-0060-5.CrossRef
14.
Xu H, Yang W, Perez-Andreu V, Devidas M, Fan Y, Pei D, Scheet P, Burchard EG, Eng C, Huntsman S, Torgerson DG, Dean M, Winick NJ, Martin PL, Camitta BM, Bowman WP, Willman CL, Carroll WL, Mullighan CG, Bhojwani D, Hunger SP, Pui CH, Evans WE, Relling MV, Loh ML, Yang JJ: Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst. 2013, 105: 733-742. 10.1093/jnci/djt042.CrossRefPubMedPubMedCentral
15.
Emerenciano M, Meyer C, Mansur MB, Marschalek R, Pombo-de-Oliveira MS, Brazilian Collaborative Study Group of Infant Acute Leukaemia: The distribution of MLL breakpoints correlates with outcome in infant acute leukaemia. Br J Haematol. 2013, 161: 224-236. 10.1111/bjh.12250.CrossRefPubMed
16.
Meyer C, Schneider B, Reichel M, Angermueller S, Strehl S, Schnittger S, Schoch C, Jansen MW, van Dongen JJ, Pieters R, Haas OA, Dingermann T, Klingebiel T, Marschalek R: Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Pro Natl Acad Sci USA. 2005, 102: 449-454. 10.1073/pnas.0406994102.CrossRef
17.
Buffler PA, Kwan ML, Reynolds P, Urayama KY: Environmental and genetic risk factors for childhood leukemia: appraising the evidence. Cancer Invest. 2005, 23: 60-75. 10.1081/CNV-46402.CrossRefPubMed
18.
Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Tomlinson IP, Taylor M, Greaves M, Houlston RS: Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009, 41: 1006-1010. 10.1038/ng.430.CrossRefPubMedPubMedCentral
19.
Trevino LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, Willman C, Neale G, Downing J, Raimondi SC, Pui CH, Evans WE, Relling MV: Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009, 41: 1001-1005. 10.1038/ng.432.CrossRefPubMedPubMedCentral
20.
Prasad RB, Hosking FJ, Vijayakrishnan J, Papaemmanuil E, Koehler R, Greaves M, Sheridan E, Gast A, Kinsey SE, Lightfoot T, Roman E, Taylor M, Pritchard-Jones K, Stanulla M, Schrappe M, Bartram CR, Houlston RS, Kumar R, Hemminki K: Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood. 2010, 115: 1765-1767. 10.1182/blood-2009-09-241513.CrossRefPubMed
21.
Pastorczak A, Gorniak P, Sherborne A, Hosking F, Trelińska J, Lejman M, Sczepański T, Borowiec M, Fendler W, Kowalczyk J, Houlston RS, Mynarski W: Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population. Leuk Res. 2011, 35: 1534-1536. 10.1016/j.leukres.2011.07.034.CrossRefPubMed
22.
Wang Y, Chen J, Li J, Deng J, Rui Y, Lu Q, Wang M, Tong N, Zhang Z, Fang Y: Association of three polymorphisms in ARID5B, IKZF1 and CEBPE with the risk of childhood acute lymphoblastic leukemia in a Chinese population. Gene. 2013, 524: 203-207. 10.1016/j.gene.2013.04.028.CrossRefPubMed
23.
Chokkalingam AP, Hsu L, Metayer C, Hansen HM, Month SR, Barcellos LF, Wiemels JL, Buffler PA: Genetic variants in ARID5B and CEBPE are childhood ALL susceptibility loci in Hispanics. Cancer Causes Control. 2013, 24: 1789-1795. 10.1007/s10552-013-0256-3.CrossRefPubMedPubMedCentral
24.
Healy J, Richer C, Bourgey M, Kritikou EA, Sinnett D: Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia. Haematologica. 2010, 95: 1608-1611. 10.3324/haematol.2010.022459.CrossRefPubMedPubMedCentral
25.
Lautner-Csorba O, Gezsi A, Semsei AF, Antal P, Erdélyi DJ, Schermann G, Kutszegi N, Csordás K, Hegyi M, Kovács G, Falus A, Szalai C: Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance. BMC Med Genomics. 2012, 5: 42-10.1186/1755-8794-5-42.CrossRefPubMedPubMedCentral
26.
27.
Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cavé H, Dastugue N, Hasle H, Kaspers GL, Lessard M, Michaux L, Vyas P, van Wering E, Zwaan CM, Golub TR, Orkin SH: Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A. 2006, 103: 3339-3344. 10.1073/pnas.0511150103.CrossRefPubMedPubMedCentral
28.
Chang LW, Payton JE, Yuan W, Ley TJ, Nagarajan R, Stormo GD: Computational identification of the normal and perturbed genetic networks involved in myeloid differentiation and acute promyelocytic leukemia. Genome Biol. 2008, 9: R38-10.1186/gb-2008-9-2-r38.CrossRefPubMedPubMedCentral
29.
Biondi A, Cimino G, Pieters R, Pui CH: Biological and therapeutic aspects of infant leukemia. Blood. 2000, 96: 24-33.PubMed
30.
Emerenciano M, Agudelo Arias DP, Coser VM, de Brito GD, Macedo Silva ML, Pombo-de-Oliveira MS: Molecular cytogenetic findings of acute leukemia included in the Brazilian Collaborative Study Group of Infant acute leukemia. Pediatr Blood Cancer. 2006, 47: 549-554. 10.1002/pbc.20654.CrossRefPubMed
31.
Rudant J, Orsi L, Bonaventure A, Goujon-Bellec S, Corda E, Baruchel A, Bertrand Y, Nelken B, Robert A, Michel G, Sirvent N, Chastagner P, Ducassou S, Rialland X, Hémon D, Leverger G, Clavel J: Are ARID5B and IKZF1 polymorphisms also associated with childhood acute myeloblastic leukemia: the ESCALE study (SFCE). Leukemia. 2013, 27: 746-748. 10.1038/leu.2012.244.CrossRefPubMed
32.
Meyer C, Hofmann J, Burmeister T, Gröger D, Park TS, Emerenciano M, Pombo De Oliveira M, Renneville A, Villarese P, Macintyre E, Cave H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh SH, Tsaur G, Fechina L, van der Velden VHJ, van Dongen JJM, Delabesse E, Binato R, Silva MLM, Kustanovich A, Aleinikova O, Harris MH, Lund-Aho T, Juvonen V: The MLL recombinome of acute leukemias in 2013. Leukemia. 2013, 27: 2165-2176. 10.1038/leu.2013.135.CrossRefPubMedPubMedCentral
Metadata
Title
ARID5B polymorphism confers an increased risk to acquire specific MLL rearrangements in early childhood leukemia
Authors
Mariana Emerenciano
Thayana Conceição Barbosa
Bruno Almeida Lopes
Caroline Barbieri Blunck
Alessandra Faro
Camilla Andrade
Claus Meyer
Rolf Marschalek
Maria S Pombo-de-Oliveira
The Brazilian Collaborative Study Group of Infant Acute Leukemia
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-127

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carcinoma xenografts exposed to surgical trauma

Research article

Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer

Research article

Population mixing for leukaemia, lymphoma and CNS tumours in teenagers and young adults in England, 1996–2005

Research article

Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells – a preclinical MR study in mice

Research article

Obesity is a significant risk factor for breast cancer in Arab women

Research article

Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits